Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast

The use of immune checkpoint inhibitors (ICIs) has hugely incremented as it has become the standard therapy for a wide range of cancer types. Such monoclonal antibodies act against inhibitory immune receptors cytotoxic T-lymphocyte antigen 4 (CTLA-4) (ipilimumab and tremelimumab) and programmed cell death 1 (PD-1) (nivolumab and pembrolizumab) by boosting the immune response of T cells [1]. Despite favourable oncological outcomes, these treatments have also been associated with a unique spectrum of side-effects known as immune-related adverse events (irAEs) [2].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research